Salmonella-based Anticancer Vaccines and their Efficacy
DOI:
https://doi.org/10.17140/VROJ-4-111Keywords:
Cancer, Vaccine, Bacteria, Salmonella, Apoptosis, Immune responses, Cancer therapy efficacyAbstract
Surgery, chemotherapy, and radiotherapy are successfully used to treat patients with tumors or cancers. However, the innovation
of more potent therapeutic modalities is essential for the efficient treatment of patients with advanced cancers. More than two
centuries ago, bacteria have been observed to have beneficial effects in some cancer patients. Virulence factors of some bacteria
and their infectious behavior in the body suggest their effectiveness in tumor suppression. At present, bacillus calmette-guérin
(BCG), a live attenuated strain of Mycobacterium bovis, is currently used to treat bladder cancer. Some other bacteria have also been
found to have antitumor activities. Anaerobic bacteria can colonize solid tumors and exert an intrinsic antitumor effect. Salmonella
is the most studied bacterium in the field of bacterial anticancer therapy in preclinical studies. In this article, we discuss progress
in the development of bacterial anticancer vaccines, especially Salmonella-based vaccines, their antitumor efficacy, and mechanisms
involved in vaccine-mediated cancer cell death.
References
Farashi-Bonab S, Khansari N. Anticancer dendritic cell vaccines producing effective antitumor T-cell responses. Int J Vaccines Vaccin. 2017; 4(3): 00081.doi: 10.15406/ijvv.2017.04.00081
Dye ES. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T-cells temporarily causes the destruction of already disseminated tumor cells. J Immunol. 1986; 136(4): 1510-1515.
Berendt MJ, North RJ. T-cell-mediated suppression of anti-tu-mor immunity. An explanation for progressive growth of an im-munogenic tumor. J Exp Med. 1980; 151(1): 69-80.
Dye ES, North RJ. Specificity of the T-cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukoc Biol. 1984; 36(1): 27-37.
Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associ-ated with the absence of lymph node metastases in patients with large early stage cervical cancer. Cancer Res. 2007; 67(1): 354-361. doi: 10.1158/0008-5472.CAN-06-3388
Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tu-mourinfltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 2003; 52(7): 423-428. doi: 10.1007/s00262-003-0388-5
Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005; 437(7055): 141-146. doi: 10.1038/nature03954
Kline J, Brown IE, Zha YY, et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 mela-noma. Clin Cancer Res. 2008; 14(10): 3156-3167. doi: 10.1158/1078- 0432.CCR-07-4696
Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of Review | Volume 4 | Number 1| antigenic cancer cells. J Exp Med. 1992; 175(1): 139-146.
Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002; 3(11): 999-1005. doi: 10.1038%2Fni1102-999
Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004; 22(6): 1136-1151. doi: 10.1200/JCO.2004.10.041
Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor out-come for patients with renal cell carcinoma. Clin Cancer Res. 2007; 13(6): 1757-1761. doi: 10.1158/1078-0432.CCR-06-2599
Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 li-gand interaction contributes to immunosuppressive microenviron-ment of Hodgkin lymphoma. Blood. 2008; 111(6): 3220-3224. doi: 10.1182/blood-2007-05-085159
Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor anti-gen-specific CD8 T-cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8): 1537- 1544. doi: 10.1182/blood-2008-12-195792
Taube JM, Anders RA, Young GD, et al. Colocalization of in-flammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune es-cape. Sci Transl Med. 2012; 4(127): 127ra37. doi: 10.1126/scitrans-lmed.3003689
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26): 2443-2454. doi: 10.1056/NEJMoa1200690
Farashi-Bonab S, Khansari N. Regulatory T-cells in cancer pa-tients and their roles in cancer development/progression. MOJ Im-munol. 2014; 1(4): 00024. doi: 10.15406/moji.2014.01.00024
Farashi-Bonab S, Khansari N. Improving of antitumor immu-nity and therapeutic efficacy of cancer vaccines and adoptive im-munotherapies using monoclonal antibodies. MOJ Immunol. 2015; 2(5): 00062. doi: 10.15406/moji.2015.02.00062
Farashi-Bonab S, Khansari N. Dendritic cell maturation is a critical step in dendritic cell vaccine preparation for cancer therapy. Vaccin Res Open J. 2016; 1(1): 25-32.
Punj V, Bhattacharyya S, Saint-Dic D, et al. Bacterial cupre-doxinazurin as an inducer of apoptosis and regression in human breast cancer. Oncogene. 2004; 23(13): 2367-2378. doi: 10.1038/ sj.onc.1207376
Cho JH, Lee MH, Cho YJ, et al. The bacterial protein azur-in enhances sensitivity of oral squamous carcinoma cells to an-ticancer drugs. Yonsei Med J. 2011; 52(5): 773-778. doi: 10.3349/ ymj.2011.52.5.773 Review | Volume 4 | Number 1| Farashi-Bonab S, et al
Yamada T, Fialho AM, Punj V, et al. Internalization of bacterial redox protein azurin in mammalian cells: Entry domain and speci-ficity. Cell Microbiol. 2005; 7(10): 1418-1431. doi: 10.1111/j.1462- 5822.2005.00567.x
Yamada T, Goto M, Punj V, et al. The bacterial redox pro-tein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppres-sor protein p53. Infect Immun. 2002; 70(12): 7054-7062. doi: 10.1128%2FIAI.70.12.7054-7062.2002
Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: Clinical results. Adv Exp Med Biol. 2010; 667:111-123. doi: 10.1007/978-1-4419-1603-7_10
Nishikawa H, Sato E, Briones G, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for thera-peutic cancer vaccines. J Clin Invest. 2006; 116(7): 1946-1954. doi: 10.1172/JCI28045
Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Lis-teria vaccine (ANZ-100) and a live-attenuated Listeria vaccine ex-pressing mesothelin (CRS-207) for advanced cancers: phase I stud-ies of safety and immune induction. Clin Cancer Res. 2012; 18(3): 858-868. doi: 10.1158/1078-0432.CCR-11-2121
Morales A, Eidinger D, Bruce AW. Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116(2): 180-183.
Rayn KN, Hale GR, Grave GP, Agarwal PK. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018; 34(1): 11-19. doi: 10.4103%2Fiju.IJU_296_17
Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Ef-fect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med. 1947; 66(2): 461-467.
Malmgren RA, Flanigan CC. Localization of the vegetative form of clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res.1955; 15(7): 473-478.
Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically in-duced rat mammary tumors. Breast Cancer Res Treat. 2001; 66(2): 165-170.
Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimen-tal tumors. Proc Natl Acad Sci U S A. 2001; 98(26): 15155-15160. doi: 10.1073/pnas.251543698
Yu YA, Timiryasova T, Zhang Q, Beltz R, Szalay AA. Optical imaging: Bacteria, viruses, and mammalian cells encoding light-emitting proteins reveal the locations of primary tumors and me-tastases in animals. Anal Bioanal Chem. 2003; 377(6): 964-972. doi: 10.1007/s00216-003-2065-0
Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nature Biotech. 2004; 22(3): 313-320. doi: 10.1038/nbt937
Yu YA, Zhang Q, Szalay AA. Establishment and character-ization of conditions required for tumor colonization by intrave-nously delivered bacteria. Biotechnol Bioeng. 2008; 100(3): 567-578. doi: 10.1002/bit.21785
Stritzker J, Weibel S, Hill PJ, et al. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol. 2007; 297(3): 151-162. doi: 10.1016/j.ijmm.2007.01.008
Leschner S, Westphal K, Dietrich N, et al. Tumor invasion of Salmonella enteric serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One. 2009; 4(8): e6692. doi: 10.1371/journal.pone.0006692
Crull K, Bumann D, Weiss S. Influence of infection route and virulence factors on colonization of solid tumors by Salmonella en-terica serovar Typhimurium. FEMS Immunol Med Microbiol. 2011; 62(1): 75-83. doi: 10.1111/j.1574-695X.2011.00790.x
Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther. 2014; 39(8): 745-750. doi: 10.1111/apt.12655
Mughini-Gras L, Schaapveld M, Kramers J, et al. Increased co-lon cancer risk after severe Salmonella infection. PLoS One. 2018; 13(1): e0189721. doi: 10.1371/journal.pone.0189721
Crull K, Weiss S. Antibiotic control of tumor-colonizing Salmo-nella enterica serovar Typhimurium. Exp Biol Med (Maywood). 2011; 236(11): 1282-1290. doi: 10.1258/ebm.2011.011111
Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmo-nella with suppressed virulence and TNF-alpha induction retain tumor-targeting in vivo. Nat Biotechnol. 1999; 17(1): 37-41. doi: 10.1038/5205
Frahm M, Felgner S, Kocijancic D, et al. Efficiency of con-ditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy. MBio. 2015; 6(2). pii:e00254- pii:e00315. doi: 10.1128/mBio.00254-15
Clairmont C, Lee KC, Pike J, et al. Biodistribution and ge-netic stability of the novel antitumor agent VNP20009, a geneti-cally modified strain of Salmonella typhimurium. J Infect Dis. 2000; 181(6): 1996-2002.
Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA. 2005; 102(3): 755-760. doi: 10.1073/pnas.0408422102 10 Farashi-Bonab S, et al
Zhong Z, Kazmierczak RA, Dino A, et al. Salmonella-hosT-cell interactions, changes in hosT-cell architecture, and destruction of prostate tumor cells with genetically altered Salmonella. Microsc Microanal. 2007; 13(5): 372-383. doi: 10.1017/S1431927607070833
Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002; 20(1): 142-152. doi: 10.1200/JCO.2002.20.1.142
Toneri M, Miwa S, Zhang Y, et al. Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models. Oncotarget. 2015; 6(31): 31335- 31343. doi: 10.18632/oncotarget.5866
Liu T, Chopra AK. An enteric pathogen Salmonella enterica se-rovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4 T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. Cancer Gene Ther. 2010; 17(2): 97-108. doi: 10.1038/cgt.2009.58
Di Virgilio F. Purines, purinergic receptors, and cancer. Cancer Res. 2012; 72(21): 5441-5447. doi: 10.1158/0008-5472.CAN-12-
Luo X, Li Z, Lin S, et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res. 2001; 12(11-12): 501-508.
Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella ty-phimurium. J Immunother. 2002; 25(3): 218-225. doi: 10.1097%2F01. CJI.0000014623.45316.93
Fu W, Chu L, Han X, Liu X, Ren D. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmo-nella enterica serovar typhimurium in murine tumor models. J Gene Med. 2008; 10(6): 690-701. doi: 10.1002/jgm.1191
Gentschev I, Fensterle J, Schmidt A, et al. Use of a recombi-nant Salmonella enterica serovar typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice. BMC Cancer. 2005; 5: 15. doi: 10.1186/1471-2407-5-15
Fensterle J, Bergmann B, Yone CL, et al. Cancer immunothera-py based on recombinant Salmonella enterica serovar typhimurium aroA strains secreting prostate-specific antigen and cholera tox-in subunit B. Cancer Gene Ther. 2008; 15(2):85-93. doi: 10.1038/ sj.cgt.7701109
Avogadri F, Mittal D, Saccheri F, et al. Intra-tumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. Eur J Immu-nol. 2008; 38(7): 1937-1947. doi: 10.1002/eji.200738035 Review | Volume 4 | Number 1|
Saccheri F, Pozzi C, Avogadri F, et al. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitu-mor immunity. Sci Transl Med. 2010; 2(44): 44ra57. doi: 10.1126/ scitranslmed.3000739
Binder DC, Engels B, Arina A, et al. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endog-enous T-cells to reject long-established cancer. Cancer Immunol Res. 2013; 1(2): 123-133. doi: 10.1158/2326-6066.CIR-13-0058
Yoon W, Yoo Y, Chae YS, Kee SH, Kim B. Therapeutic advan-tage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment. Ann Oncol. 2018; 29(9): 2010-2017. doi: 10.1093/annonc/mdy240
Monack DM, Raupach B, Hromockyj AE, Falkow S. Salmonella typhimurium invasion induces apoptosis in infected macrophages. Proc Natl Acad Sci U S A. 1996; 93(18): 9833-9838.
Hersh D, Monack DM, Smith MR, et al. The Salmonella in-vasion SipB induces macrophage apoptosis by binding to caspase Submit your article to this journal | https://openventio.org/submit-manuscript/ Review | Volume 4 | Number 1| Farashi-Bonab S, et al 1. Proc Natl Acad Sci USA. 1999; 96(5): 2396-2401.doi: 10.1073/ pnas.96.5.2396
Kim JM, Eckmann L, Savidge TC, et al. Apoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest. 1998; 102(10): 1815-1823. doi: 10.1172/JCI2466
Kepp O, Tesniere A, Schlemmer F, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009; 14(4): 364-375. doi: 10.1007/s10495-008-0303-9
Jang MJ, Kim JE, Chung YH, et al. Dendritic cells stimulated with outer membrane protein A (OmpA) of Salmonella typhimuri-um generate effective anti tumor immunity. Vaccine. 2011; 29(13): 2400-2410. doi: 10.1016/j.vaccine.2011.01.036
Hong EH, Chang SY, Lee BR, et al. Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmen-tal shift from immune suppressive to immunogenic. Vaccine. 2013; 31(10): 1377-1384. doi: 10.1016/j.vaccine.2013.01.006
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.